Etoricoxib with L-dopa for Parkinson's disease
Official title: Clinical Study to Evaluate Safety and Efficacy of Etoricoxib in Patients With Parkinson's Disease Treated With Conventional Treatment
Run by Tanta University · NCT07370532 · Data updated 2026-11-12
This trial will test whether adding etoricoxib to usual Parkinson's treatment lowers inflammation markers and helps adults with Parkinson's disease.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 50 Years to 70 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Al Mansurah) |
| Status | Recruiting |
| Started | January 30, 2026 |
| Main results expected | November 10, 2027 |
| Study ends | November 20, 2027 |
| Registry record updated | April 8, 2026 |
| Trial ID | NCT07370532 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age 18 or older) with a clinical diagnosis of Parkinson's disease by UPDRS who are not pregnant or breastfeeding and who do not have significant liver or kidney impairment may be eligible.
✕Probably not a fit
People who are pregnant or breastfeeding, have significant liver or kidney dysfunction, are using other anti-inflammatory drugs, have drug allergies to the study medications, or have active substance abuse are unlikely to qualify or benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 2, single-site interventional trial testing the COX-2 inhibitor etoricoxib alongside L-dopa in adults diagnosed with Parkinson's disease. The study will enroll patients meeting clinical Parkinson's criteria (using the UPDRS) and excludes pregnant or breastfeeding people, those with significant liver or kidney problems, current users of other anti-inflammatory drugs, and people with substance abuse or allergies to the study medications. Outcomes likely include changes in inflammatory biomarkers such as HMGB1 and receptor pathways (TLR4/RAGE) and clinical Parkinson's measures. The trial is being conducted at Mansoura University in Al Mansurah, Egypt.
Why it matters
Potential benefit: If successful, the treatment could reduce neuroinflammation and potentially improve symptoms or slow progression in some people with Parkinson's disease.
How similar studies have gone: Preclinical work and small clinical studies of COX-2 inhibitors suggest possible anti-inflammatory effects, but clear clinical benefit in Parkinson's disease remains unproven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years. * Both male and female will be included. * Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale. Exclusion Criteria: * Breast feeding * Patients with significant liver and kidney function abnormalities. * Alcohol and / or drug abusers. * Patients with known allergy to the study medications * Pregnant women and women with planned pregnancy. * Patients who are currently using other anti-inflammatory drugs.
Where it's running
-
Mansoura University
Al Mansurah, Egypt Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Tributyrin for PSP: a virtual, early-phase study
This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.
-
A look at why Lewy body conditions cause visual hallucinations
This study tests brain‑imaging in people with Lewy body diseases who do or don’t experience visual hallucinations, and in healthy volunteers, to see how brain networks might create these images.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
Can hippotherapy improve mobility, gait, balance, and quality of life in people with Parkinson's disease?
This pilot trial tests whether adding horse-assisted therapy to standard rehab helps mobility, gait, balance, and perceived health in adults with Parkinson's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.